Net margin is calculated as Net Income divided by its Revenue. 10x Genomics's Net Income for the
three
months ended in Mar. 2026 was MXN-243 Mil. 10x Genomics's Revenue for the
three
months ended in Mar. 2026 was MXN2,720 Mil. Therefore, 10x Genomics's net margin for the quarter that ended in Mar. 2026 was -8.93%.
The historical rank and industry rank for 10x Genomics's Net Margin % or its related term are showing as below:
MEX:TXG'
s Net Margin % Range Over the Past 10 Years
Min: -181.61 Med: -29.9 Max: -3.55
Current: -3.55
MEX:TXG's Net Margin % is ranked worse than 69.91% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs MEX:TXG: -3.55
10x Genomics (MEX:TXG) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
10x Genomics Net Margin % Related Terms
10x Genomics Net Margin % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TXG vs WAY, DOCS, HNGE: Net Margin % Comparison
For the Health Information Services subindustry, 10x Genomics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Net Margin % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (MEX:TXG) has a Net Margin % of -8.93% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #467 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 69.9%.
Is 10x Genomics' Net Margin % too high?
10x Genomics' current Net Margin % is -8.93%. Based on the distribution chart, 10x Genomics ranks #467 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, 10x Genomics has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Net Margin % compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #467 out of 668 companies for Net Margin %. This places 10x Genomics in the lower half of its industry. The industry median Net Margin % is 2.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Net Margin % is -8.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
10x Genomics (MEX:TXG) has a current Net Margin % of -8.93%. The stock's GF Value™ is MXN200.14, compared to a current price of MXN335.54 — trading 67.7% above its estimated fair value. The current Net Margin % is -8.93%. 10x Genomics' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For 10x Genomics (MEX:TXG), the current Net Margin % is -8.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (MEX:TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of MXN335.54 is trading 67.7% above its estimated GF Value™ of MXN200.14.
Key valuation signals for MEX:TXG:
Net Margin %: -8.93%
GF Value™: MXN200.14 vs. price of MXN335.54 (67.7% above fair value)
No single metric tells the full story. See the MEX:TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
68GF Score
Get the complete analysis for MEX:TXG
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TXG has been successfully added to your 
